Lorillard Inc

Lorillard — Investor Day (June 2013)

168 slides from Lorillard's investor day presentation, Jun 27, 2013

  1. Slide 1: Investor Day

    Investor Day | June 27, 2013 Lelia 1

  2. Slide 2: Agenda

    Agenda Introduction Strategic Plan Update Regulatory Update Legal Update Financial Guidance (Lorillard-Style) Additional Q&A Bob Bannon – Investor Relations Murray Kessler – Chairman, President & CEO Neil Wilcox– SVP, Chief Compliance Officer Bill True – SVP, R&D Ron Milstein – EVP, Legal & General

  3. Slide 3: Safe Harbor Disclaimer

    Safe Harbor Disclaimer of You the are Private cautioned Securities that certain Litigation statements Reform Act made of 1995. in this Forward-looking presentation are statements “forward-looking” include, statements without limitation, within the any meaning words statement “expect”, that may “inte

  4. Slide 4: Murray S. Kessler

    Murray S. Kessler Chairman, President and Chief Executive Officer

  5. Slide 5: Two Years Ago We Established A Powerful Vision

    Two Years Ago We Established A Powerful Vision “To Responsibly Bring Newport Pleasure To All Adult Smokers” “Responsibly” • Compliance • Quality • Shareholders • Adult Consumers “Bring” A call to action Excellence across the value chain Superior products Preferred by adult consumers Consistent messa

  6. Slide 6: Goal Of Consistently Delivering A Double-digit Shareholder Return

    With A Goal Of Consistently Delivering A Double-digit Shareholder Return Over The Long-Term EPS + Dividend Yield Shareholder Total Return 6—12% 4—5% 10—17%

  7. Slide 7: Three Core Strategies Were Set In Place To Pursue Our Vision

    Three Core Strategies Were Set In Place To Pursue Our Vision Grow Protect The & Core Processes Build Out Capabilities and Carefully Pursue Adjacencies Close-in

  8. Slide 8: Strategy Based On Maintaining Strength In Full Flavor Menthol In Core Geographies

    Source: MSA, Inc. Excel retail database. Fundamentally, The Strategy Was Based On Maintaining Our Strength In Full Flavor Menthol In Core Geographies 2010 Total: 288B Units Core Markets Non-Core Markets Flavor Strength Flavor Type Premium Full Flavor Menthol 30B Total Units Newport Share: 74% Premiu

  9. Slide 9: Pursuing Adjacencies In Other Industry Segments

    And Pursuing Adjacencies In Other Industry Segments As Well As Through Geographic Expansion 2010 U.S. Tobacco Market Segmentation 15.7 B Packs/Cans 100% 80% 60% 40% 20% 0% RJR Altria RJR Altria 91.7 % RJR Altria RJR Altria All Others RJR Altria Altria RJR Others 0.3 % 8.0 % [Graphic Appears Here] So

  10. Slide 10: Four Key Priorities For Adjacency Expansion

    We Identified Four Key Priorities For Adjacency Expansion Build Newport Share in Non-Core Geographies Invest to breakthrough in non-menthol Strengthen our less than full-flavor menthol franchise Opportunistically pursue non-cigarette adjacencies Source: Lorillard filings. * Earnings per share data a

  11. Slide 11: Strategic Plan Accelerated Strong Historic Financial Performance

    The Implementation Of Our Strategic Plan Has Accelerated An Already Strong Historic Financial Performance Annual Adjusted Earnings Per Share* Retail Market Share +13.9% CAGR +6.5% CAGR +0.6 pts per year +0.8 pts per year $3.00 $2.50 $2.00 $1.50 $1.00 2006 2007 2008 2009 2010 2011 2012 2006 2007 2008

  12. Slide 12: Consistently Rewarding Shareholders

    That Continues To Consistently Reward Shareholders Annualized Dividend Per Share Cumulative Cash Returned $3.00 +79% $2.20 $2.07 $2.00 $1.73 $1.50 $1.33 $1.23 $1.00 Q3 2008 Q3 2009 Q3 2010 Q1 2011 Q1 2012 Q1 2013 In millions $7,310 $7,500 $5,925 $5,000 $4,191 $3,615 $3,613 $2,254 $2,026 $2,500 $713

  13. Slide 13: Consistently Outperforms Peers

    That Consistently Outperforms Peers Five Year Peer Comparison 2007-2012 Net Sales (ex-FET) Adj. Operating Income Adjusted EPS 41.3% 15.0% 47.8% 49.8% 21.7% 64.0% 49.3% 30.0% LO MO RAI -8.0% Source: Bloomberg and company reports. See Appendix A for further discussion of adjustments.

  14. Slide 14: Significant Increases In Shareholder Value

    And That Ultimately Contributed To Significant Increases In Shareholder Value Stock Price P/E Ratio Market Cap (B) $27 12.1 $12.1 P/E Ratio Market Cap (B) $44 15.0 $16.4 2011 2012 2013 Source: Bloomberg. As of June 25, 2013

  15. Slide 15: Lorillard's Strategic Plan Is Working

    Because Lorillard’s Strategic Plan Is Working Newport full-flavor menthol in the core continues to remain stable despite increased menthol competition Lorillard’s geographic expansion strategy has been successful Newport’s launch into non-menthol has worked well The blu eCigs acquisition has exceede

  16. Slide 16: Lorillard's Strategic Plan Is Working

    Because Lorillard’s Strategic Plan Is Working Newport full-flavor menthol in the core continues to remain stable despite increased menthol competition Lorillard’s geographic expansion strategy has been successful Newport’s launch into non-menthol has worked well The blu eCigs acquisition has exceede

  17. Slide 17: Lorillard Competes Within The Declining Cigarette Market

    Remember, Lorillard Competes Within The Declining Cigarette Market With A Unique Product Portfolio Flavor Strength Volume (Units) 2012 100% 80% 60% 40% 20% 0% 39B 134B 69B Non-M Non- Non- Menthol Menthol Menthol Menthol Menthol Altria Reynolds Volume (Units) 100% 2012 80% 60% 40% 20% 0% 39B 134B 69B

  18. Slide 18: Full-Flavor Menthol Segment Continues To Outperform

    The Full-Flavor Menthol Segment Continues To Outperform Other Cigarette Industry Segments Volume Change 2005 vs. 2012 (Billion Volume Units) FF M FF M NFF M NFF M FF NM FF NM NFF NM NFF NM Core Non-Core Core Non-core Core Non-Core Core Non-Core Discount 1.5 -1.1 -4.0 -6.5 -10.2 -8.7 -16.8 -20.9 -20.

  19. Slide 19: Stability of the Core Remains Primary Driver Of Success

    It is the Stability of the Core and Our Stability In The Core That Remains The Primary Driver Of Our Success Premium Full-Flavor Menthol, Core States 100% All Other All Other All Other All Other 80% 60% 40% Newport Newport Newport Newport 20% 0% 2010 2011 2012 2013 YTD Newport Premium Share Full-Fla

  20. Slide 20: Primary Driver Of Newport's Stability

    Which Is A Primary Driver Of Newport’s Stability Newport Net Promoter Scores Newport Cigarettes 63 61 Loyalty Index – among most-often cigarette brand smoked Newport M Marlboro NM Camel NM Marlboro M Camel M 104 Category 96 92 Average = 100 2010 2013 Source: Lorillard proprietary research. Adult con

  21. Slide 21: Strong Newport Equity Traces To A Highly Differentiated Product

    Strong Newport Equity Traces To A Highly Differentiated Product Brand attribute preferences among premium menthol smokers Attribute Newport Menthol #2 Menthol Brand #3 Menthol Brand Is always fresh tasting Is a real pleasure to smoke Has taste that is consistent Is very smooth Is made only from the

  22. Slide 22: Than Just Menthol

    Than Just Menthol Brand attribute preferences among Newport Menthol Smokers Attribute Newport Non-Menthol #1 Non-Menthol Brand #2 Non-Menthol Brand OverallSatisfaction Strength of Taste is Just Right Strength of Taste is Too Weak Source: Lorillard National Product Opinion Panel, September 2009.

  23. Slide 23: A Highly Differentiated Consumer

    Attribute Newport Menthol Non- Menthol Male 111 99 117 Female 90 101 84 Large Metro 121 105 89 Non-Metro 65 90 133 Northeast 173 123 85 South 108 121 110 Midwest 97 98 108 West 29 48 88 White 49 78 120 African American 447 259 20 And A Highly Differentiated Consumer Index to U.S. Demographic Overvie

  24. Slide 24: Competitors Have Dramatically Increased Discounting in Menthol Segment

    So While Competitors Have Dramatically Increased Their Discounting in The Menthol Segment… Percentage of competitive premium menthol brands sold at a discount to the typical premium price* 50% 40% 30% 20% 10% 2009 2010 2011 2012 YTD 2013 Source: MSA, Inc. Excel retail database YTD through 6/1/2013.

  25. Slide 25: Lorillard & Newport Continue To Gain Menthol Segment Share

    Source: MSA, Inc. Excel retail database, year-to-date 2013 as of June 1, 2013. Lorillard & Newport Have Continued To Gain Share Of The Menthol Segment, Which Has Also Gained Share Share of the Menthol Segment Menthol Segment Share of Cigarette Market Share of the Menthol Segment Newport Lorillard 32

  26. Slide 26: Without Heavily Discounting Like Competitors

    Without Heavily Discounting Like Competitors Percentage of Menthol Volume Sold at Full Price* 100% 95% 80% 59% 60% 54% 40% Newport #2 Menthol #3 Menthol Brand Brand Source: MSA, Inc. Excel retail database, year-to-date through 6/1/2013. Full price is defined as within 50 cents per pack of the most c

  27. Slide 27: Emphasize Brand-Building Over Discounting

    Going Forward, Lorillard Will Continue To Emphasize Brand-Building Over Discounting Refreshed Print Advertising Program More Aggressive Direct Mail Campaigns Expanded Product Offerings

  28. Slide 28: In Order To Keep Newport Relevant

    In Order To Keep Newport Relevant! Newport market share among adult smokers age 18+ and 18-25 25% 22.5% 20% 19.3% 18.9% 19.9% 20.8% 15% 13.3% 14.1% 11.6% 12.6% 12.1% 10% 5% 0% 2007 2008 2009 2010 2011 18+ 18-25 Source: National Survey on Drug Use and Health (NSDUH) 2007-2011

  29. Slide 29: Lorillard's Strategic Plan Is Working

    Lorillard’s Strategic Plan Is Working Newport full-flavor menthol in the core continues to remain stable despite increased menthol competition Lorillard’s geographic expansion strategy has been successful Newport’s launch into non-menthol has worked well The blu eCigs acquisition has exceeded expect

  30. Slide 30: Newport & Total Lorillard Went From Declining To Profitably Growing In Non-core

    Newport & Total Lorillard Went From Declining To Profitably Growing In The Non-core Results from geographic expansion strategy in the non-core Volume Trends Market Share 5.5% 5.0% 4.3% Newport -4.9% 18.6% 7.3% 5.5% Total -1.1% Lorillard Pre Post Pre Post Source: MSA, Inc. Excel retail database. Pre-

  31. Slide 31: Total Company Approach Outside The Core

    Driven By A Total Company Approach Outside The Core • 32,000 new retail plans nce 2009 in the non-core • Eliminating Newport’s price disadvantage in non-core • Launching Newport Red

  32. Slide 32: Lorillard's Strategic Plan Is Working

    Lorillard’s Strategic Plan Is Working pite increased menthol competition 2. Lorillard’s geographic expansion strategy has been successful 3. Newport’s launch into non-menthol has worked well 4. The blu eCigs acquisition has exceeded expectations and positions Lorillard as the clear leader in the rap

  33. Slide 33: Newport Has Gone From Nothing To A 5% Share Of Full-Flavor NM

    Newport Has Gone From Nothing To A 5% Share Of The Full-Flavor NM Segment (9% in Core) Total U.S. 100% Other Other Winston Newport Winston 80% Camel Camel 60% 40% Marlboro Marlboro 20% 0% 2010 YTD 2013 Core Markets 100% Other Other Winston Newport 80% Winston Camel Camel 60% 40% Marlboro Marlboro 20

  34. Slide 34: Newport Red Is A Meaningful Contributor

    And Because Newport Red Is Highly It Is A Meaningful Contributor Contribution to … 2012 Unit Volume (B) 2.2 2012 Percent of Lorillard 5.7% domestic unit volume 2013 Retail Market Share 0.9 pts Source of Volume… Premium Brands 74% Competitive Brands 90% Intend to purchase 80% Adopted as usual brand 6

  35. Slide 35: Franchise Consumers Strongly Prefer the Product

    And, Like Newport Menthol, Franchise Consumers Strongly Prefer the Product Brand attribute preferences among Newport Non-Menthol Smokers Marlboro Attribute Non- Camel Red Menthol OVerall satisfaction ? Liking of overall taste ? Liking of strength of taste ? smoothness ?

  36. Slide 36: Non-Menthol Gold is the Next Big Opportunity

    Non-Menthol Gold is the Next Big Opportunity for Lorillard Premium Non-Menthol Non-Full Flavor Units by Brand 89 B units 100% Winston Other 80% Camel 60% 40% Marlboro 20% 0% ]

  37. Slide 37: Newport Non-Menthol Gold Deemed Substantially Equivalent by the FDA

    Newport Non-Menthol Gold Has Been Deemed Substantially Equivalent by the FDA and Authorized for Marketing

  38. Slide 38: Newport Non Menthol Gold: Right Product at the Right Time

    Newport Non Menthol Gold …. The Right Product at the Right Time in the Right Package Taste – Overall satisfaction rating higher than the leading brand Packaging – Preferred by a margin of 2:1 in consumer test Pricing – Priced in-line with Newport Non-Menthol Timing - Second half of 2013 hol Product

  39. Slide 39: Lorillard's Strategic Plan Is Working

    Lorillard’s Strategic Plan Is Working pite increased menthol competition 2. Lorillard’s geographic expansion strategy has been successful 3. Newport’s launch into non-menthol has worked well 4. The blu eCigs acquisition has exceeded expectations and positions Lorillard as the clear leader in the rap

  40. Slide 40: Evaluating Close-In Adjacencies Most Related To Our Core

    Two Years Ago, We Said That We Would Evaluate Close-In Adjacencies Most Related To Our Core Core menthol Full flavor cigarettes 3 Steps Unrelated 2 Steps Diversification 1 Step Tobacco MST related Other CPG Other cigarette sub-segments Cigars (lighters, adjacencies etc. ) (energy drinks, etc.) Other

  41. Slide 41: Rapidly Growing e-Cigarette Category Caught Our Attention

    The Rapidly Growing e-Cigarette Category Caught Our Attention e-Cigarette U.S. Sales ($millions) $1,200 $1,000 $1B $800 $600 $500 $400 $250 $200 $100 $20 $50 $5 $0 2007 2008 2009 2010 2011 2012 E 2013 E Source: UBS Research estimates, research note dated 9/23/2012 “E-cigarette consumption could surp

  42. Slide 42: More Adult Smokers Becoming Aware And Trying e-Cigs

    As More And More Adult Smokers Were Becoming Aware And Trying e-Cigs Nearly 6 in 10 adults were aware of e-cigs in 2011 40% increase since 2010 21% of adult smokers had tried an e-cig in 2011

  43. Slide 43: Awareness, Trial, And Use Continue To Increase

    Awareness, Trial, And Use Have Continued To Dramatically Increase Since The CDC Study 2011 2013 100% Repeat Usage 100% 94% 2011 – 22% 80% 2013 – 26% 60% 43% 40% 26% 23% 20% 11% 5% 0% Aware of e-cigs Trial Use regularly (at least daily) Source: Lorillard Adult Tobacco User Survey; October 2011 (n=800

  44. Slide 44: E-cigs Have Broad Appeal Among Tobacco Consumers

    E-cigs Have Broad Appeal Among Tobacco Consumers Survey Respondent Profile among those who have tried e-cigs 100% 80% 60% 40% 20% 0% 45-54 45-54 35-44 25-34 21-24 Male Female na $100K $75-$100 $50-$75 $25-$50 $25K Tech Post-Grad College Diploma Some College H.S. Urban Suburban Rural Prior Tobacco Us

  45. Slide 45: Growth Is Being Fueled By Smoker Conversion

    Growth Is Being Fueled By Smoker Conversion e-cig Users Report Using Less or Completely Replacing Cigarettes Use Less Do Not 36% Use Less 44% Completely Replace 20% Estimate that 2.5 billion less cigarettes will be smoked in 2013 due to e-cigs Source: Lorillard adult tobacco consumer survey, October

  46. Slide 46: e-Cigs Negatively Impacting U.S. Cigarette Trends

    e-Cigs Are Large Enough To Now Be Negatively Impacting U.S. Cigarette Trends Estimated e-cig impact in Q1 2013 Adjusted Cigarette Cigarette Industry E-Cigs Industry* Pack Volume Volume Change Percent Volume Equalized Volume Change Percent (MM) from Year Ago Change to Packs (MM) from Year Ago Change

  47. Slide 47: e-Cigs Can Play A Role In Reducing Harm From Tobacco

    e-Cigs Can Play A Significant Role In Reducing The Harm From Tobacco Tobacco Continuum of Risk Tobacco Harm Reduction • FDA’s Tobacco Products Scientific Advisory Committee acknowledged there is a continuum of risk with regard to tobacco products. • “There is a strong scientific and medicinal founda

  48. Slide 48: Accumulating Evidence To Support Harm Reduction

    And There Is Accumulating Evidence To Support This Dr. Richard Carmona Dr. Elizabeth Whelan (2013) U.S. Surgeon General (2002-2006) American Council of Science and NJOY Board of Directors Health “To dismiss (e-cigarettes) and not even “They’re (e-cigarettes) a clean nicotine consider it … would be a

  49. Slide 49: Vapor vs Smoke Analysis

    For Example Vapor vs Smoke Analysis Nicotine—3% Nicotine—1% Glycerin– 2% Flavors and Combustion Flavors—11% bi-products – 41% Water—15% Water – 20% Glycerin—73% Carbon Monoxide—34% Blu eCig Leading brand of low-tar cigarettes 99 puffs 9 puffs Source: Lorillard and blu eCigs proprietary data, 2013.

  50. Slide 50: Harmful Constituents Are At Or Below Detectable Levels

    Harmful Constituents Are At Or Below Detectable Levels Market Leading Gold blu Product Class % Difference Cigarette 9 puffs (1 cigarette) 99 puffs Carbon Monoxide 27 mg < 0.1 mg * 99.6 % less Carbonyls 2.366 < 0.074 97.0 % less Phenolics 0.204 < 0.002 * 99.1 % less Volatiles 1.430 < 0.003 * 99.8 % l

  51. Slide 51: Harmful Constituents Are At Or Below Detectable Levels

    Harmful Constituents Are At Or Below Detectable Levels Market Leading GoldAt least 98%blu Productless Class % Difference Cigarette 9 puffs (1 cigarette)constituents99 puffs Carbon Monoxide 27 mg from blu< 0.1vs.mg * 99.6 % less cigarette Carbonyls 2.366 < 0.074 97.0 % less Phenolics 0.204 < 0.002 *

  52. Slide 52: Lorillard Purchased blu e-Cigs

    After Careful Evaluation, Lorillard Purchased blu e-Cigs Superior Product Highest brand awareness Unique & proprietary positioning Well-rounded portfolio Disposables & rechargeables All retail channels Potential for Lorillard to be the category leader

  53. Slide 53: blu e-Cigs Has Emerged As The Clear Leader

    Since Lorillard’s Acquisition, blu e-Cigs Has Emerged As The Clear Leader by Far In The Category Quarterly blu eCigs net sales 40%+ Market Share ~80,000 Retail Outlets $60 $57 $50 $39 $40 11% Market Share—~12,000 Retail $30 Outlets $20 $14 $10 $8 $0 Q2 2012 Q3 2012 Q4 2012 Q1 2013 Source: MSA, Inc.

  54. Slide 54: blu eCigs Double the Size of Next Closest Brand

    With A Strong Business Across All Products and Channels, blu eCigs is Double the Size of the Next Closest Brand First Quarter 2013 blu eCigs sources of dollar sales By Products Rechargeable Cartomizers Kits—27% 22% Disposables 51% By Sales Channel Other Tobacco 7% Stores- 10% Gas/Convenience Interne

  55. Slide 55: blu's Leadership in Awareness

    Beyond Sales & Share, Consumer Research Also Demonstrates blu’s Leadership in Awareness Aided brand awareness by current e-cig users 100% 86% 80% 60% 50% 46% 40% 35% 33% 29% 32% 25% 22% 22% 21% 20% 15% 0% na na blu eCigs NJOY V2Cigs GreenSmoke eSmoke Cigalectric 21st Century Source: Lorillard Adult

  56. Slide 56: blu's Leadership in Usage

    And blu’s Leadership in Usage Brand most used by those who have tried e-cigs 100% 80% 60% 40% 20% 0% Other Other Green Smoke eSmoke 21st Century eSmoke NJOY NJOY blu eCigs blu eCigs 2011 May 2013 Source: Lorillard Adult Tobacco User Survey; October 2011 (n=196) and May 2013 (n=223).

  57. Slide 57: Why Because blu Is A Brand-Builder

    Why Because blu Is A Brand-Builder

  58. Slide 58: blu Is A Brand-Builder

    blu Is A Brand-Builder

  59. Slide 59: blu Is A Brand-Builder

    blu Is A Brand-Builder

  60. Slide 60: blu's Product Is At The Forefront

    blu’s Product Is At The Forefront blu eCigs Puff-by-Puff Nicotine Yield Rechargeable Products Superior product taste & value Digital chip technology E-liquid made in USA On-the-Go recharging State-of-the-art quality controls Consistent nicotine delivery over life of product * (mg) * Nicotine Aerosol

  61. Slide 61: New Streamlined On-the-Go Rechargeable Kit

    New Streamlined On-the-Go Rechargeable Kit Will Further blu’s Technology Lead Old Pack New Pack MSRP $59.99 $34.99 Size Cigarette pack Slim as a smart phone Battery Pack charge indicator Pack & cig charge indicator Retailer margin ~20% ~30%

  62. Slide 62: blu's Technology Team In Silicon Valley Continues To Innovate

    blu’s Technology Team In Silicon Valley Continues To Constantly Innovate Proprietary technology advances to further blu’s innovation lead Areas of current development: Unique juice storage & delivery New component technologies Longer battery life Custom processor with proprietary algorithms Redundan

  63. Slide 63: The Acquisition Has Already Been Accretive

    The Acquisition Has Already Been Accretive Electronic Cigarette Segment Results FY 2012 2013-Q1 (in millions) Net Sales $ 61 $ 57 Gross Profit $ 21 $ 21 Adjusted Operating Income $ 7 $ 7 Source: Lorillard filings. See Appendix A for further discussion of adjustments

  64. Slide 64: Lorillard's Strategic Plan Is Working

    Lorillard’s Strategic Plan Is Working Newport full-flavor menthol in the core continues to remain stable despite increased menthol competition Lorillard’s geographic expansion strategy has been successful Newport’s launch into non-menthol has worked well The blu eCigs acquisition has exceeded expect

  65. Slide 65: New Adjacency Initiatives Delivered Half Of Revenue Growth

    New Adjacency Initiatives From Our Strategic Plan Have Delivered Half Of Lorillard’s Revenue Growth Net Revenue Comparison $6.6 B $5.9 B +$0.7 B 2010 2012 % From Adjacencies ($mil) • Newport Red $234 34% • blu eCigs $61 9% • Geographic Expansion $51 7% TOTAL $346 50% Source: Lorillard filings.

  66. Slide 66: Strengthened Our Cigarette Business Versus Competition

    And Helped Us Strengthen Our Cigarette Business Versus Competition Volume Change (billions of cigarettes) Pre-Strategic Plan (2005 vs. 2010) +2.2 Altria Reynolds -30 -45 Including Strategic Plan (2005 vs. 2012) +4.3 Altria Reynolds -39 -51 Source: MSA, Inc. domestic shipment data

  67. Slide 67: Lorillard's Strategic Plan Is Working

    Lorillard’s Strategic Plan Is Working Newport full-flavor menthol in the core continues to remain stable despite increased menthol competition Lorillard’s geographic expansion strategy has been successful Newport’s launch into non-menthol has worked well The blu eCigs acquisition has exceeded expect

  68. Slide 68: Significant Enhancements Made To Processes And Capabilities

    Significant Enhancements Were Made To Processes And Capabilities Preparedness For FDA/GMP Corporate Compliance Department Established New Equipment Installed in Many Areas FDA Readiness Stage & Gate Process Established Marketing Restructure R&D Reorganization Pilot Plant Upgraded New Product Capabil

  69. Slide 69: Identified As Opportunities Back In 2010

    Identified As Opportunities Back In 2010 Adjacent Adjacent Core Expansion Core Expansion Product Development Sales Execution Brand Marketing Direct Mail Regulatory Affairs

  70. Slide 70: Much Of Incremental Investment Is Behind Us

    Much Of Incremental Investment to Build Process and Capabilities is Behind Us $ millions CapEx 80 $74 60 $56 $40 2010 2011 2012 $ millions Adjusted SG&A $498 $451 $398 2010 2011 2012 Source: Lorillard filings. See Appendix A for further discussion of adjustments.

  71. Slide 71: Lorillard's Strategic Plan Is Working

    Lorillard’s Strategic Plan Is Working Newport full-flavor menthol in the core continues to remain stable despite increased menthol competition Lorillard’s geographic expansion strategy has been successful Newport’s launch into non-menthol has worked well The blu eCigs acquisition has exceeded expect

  72. Slide 72: Lorillard's Freedom To Operate Successfully Defended

    Lorillard’s Freedom To Operate Successfully Defended But An Ongoing Challenge Menthol Debate NPM Settlement Leading the Way is Reasonable e-cig Regulation Won Graphic Warnings Case TPSAC Lawsuit Successful FDA Inspections

  73. Slide 73: Lorillard's Strategic Plan Is Working

    Lorillard’s Strategic Plan Is Working Newport full-flavor menthol in the core continues to remain stable despite increased menthol competition Lorillard’s geographic expansion strategy has been successful Newport’s launch into non-menthol has worked well The blu eCigs acquisition has exceeded expect

  74. Slide 74: Lorillard's Capital Structure Continues To Be Improved

    Lorillard’s Capital Structure Continues To Be Improved 2010 2011 2012 2013- Q1 Leverage 1.0 X 1.3X 1.6 X 1.8 X* Long-Term Debt $1.77 B $2.60 B $3.11 B $3.60 B* Shares Repurchased (millions) 27.0 46.7 14.8 3.8 Dividend Payout 63% 66% 73% nm Weighted Average Interest Rate on Debt 6.2% 5.7% 5.2% 5.0%*

  75. Slide 75: Investors Rewarded Over the Long-term

    As A Result Of Lorillard’s Remarkable Brand Strength, Investors Have Been Rewarded Over the Long-term 500 +366.4% 100 300 to Indexed 200 Prices +40.5% Jan-02 Jan-03 Jan-04 Jan-05 Jan-06 Jan-07 Jan-08 Jan-09 Jan-10 Jan-11 Jan-12 Jan-13 LO S&P 500 Source: Bloomberg. From Carolina Group IPO on 1/31/200

  76. Slide 76: As Well as Over the Medium-Term

    As Well as Over the Medium-Term – Despite the Regulatory Overhang Total Return Comparison 6/2008 – 5/2013 150% 140.4% 125% 100% 95.4% 75% 50% 42.2% 25% 0% Lorillard S&P 500 Food, S&P 500 Beverage & Tobacco Source: Bloomberg. Total return data from 6/30/2008 through 5/31/2013.

  77. Slide 77: We Still Have Lots Of Running Room

    And, We Still Have Lots Of Running Room 2012 U.S. Tobacco Market Segmentation 15.1 B Packs/Cans 0.2 % 90.5 % 8.8 % 0.5 % 100% RJR RJR RJR Others 80% RJR All Others Altria RJR 60% 40% Altria Altria Altria RJR Altria 20% Altria 0% Non-Full Flavor Non-Menthol Full-Flavor MST -Cigs Non-Menthol Menthol M

  78. Slide 78: Summary

    Summary Delivering superior results despite competitive environment Gaining market share for the 11th consecutive year Launching adjacent new products to accelerate growth Continuing to be first and best in e-cigarettes with blu eCigs Remaining focused on tight cost control As always, rewarding shar

  79. Slide 79: Regulation Worries Investors

    While Lorillard’s Fundamentals Clearly Lead The Industry, Regulation Worries Investors Agenda Introduction Bob Bannon – Investor Relations Strategic Plan Update Murray Kessler – Chairman, President & CEO Regulatory Update Neil Wilcox – SVP, Chief Compliance Officer Bill True – SVP, R&D Legal Update

  80. Slide 80: Regulatory Update

    Regulatory Update Neil Wilcox, SVP & Chief Compliance Officer Bill True, SVP Research & Development June 27, 2013

  81. Slide 81: Update On The Regulatory Environment

    Update On The Regulatory Environment Lorillard’s preparations for FDA regulations Corporate Compliance infrastructure New FDA / CTP Director Substantial Equivalence (SE) FDA e-cigarettes deeming regulation Menthol

  82. Slide 82: What Has Lorillard Done To Ensure Regulatory Compliance?

    What Has Lorillard Done To Ensure Regulatory Compliance? Established a new Corporate Compliance department Recruited team to build a foundation of excellence based upon demonstrated expertise Ensured corporate policies and procedures that meet or exceed all federal, state and local regulations Estab

  83. Slide 83: Sustained Effort To Modernize And Prepare For FDA Compliance

    Lorillard’s Sustained Effort To Modernize And Prepare For FDA Compliance Implemented Modernized Equipment for NTRM (Non-Tobacco Related Material) Detection Advanced screen systems State-of-the-art sorters Microwave and magnetic detection systems

  84. Slide 84: Sustained Effort To Modernize And Prepare For FDA Compliance

    Lorillard’s Sustained Effort To Modernize And Prepare For FDA Compliance Installed Significant Engineering Upgrades Robotic Palletizers by Complex State-of-the-art Dryers RFID (Radio Frequency Identification) system upgrade Upgraded blending and menthol systems New Maker and Rod Making complexes Imp

  85. Slide 85: Sustained Effort to Modernize and Prepare for FDA Compliance

    Lorillard’s Sustained Effort to Modernize and Prepare for FDA Compliance We continue to Build our Processes and Capabilities IT Modernization In-Sourcing of R&D analyte testing Upgraded Pilot Plant Lorillard’s Manufacturing, IT and R&D are Well Prepared for FDA Regulations

  86. Slide 86: Rigorous Regulatory Compliance Preparations

    Rigorous Regulatory Compliance Preparations Prepared for FDA Inspections External consultant audits Training Internal audits Practice inspections

  87. Slide 87: Results Of Our Regulatory Compliance Preparations

    What Were The Results Of Our Regulatory Compliance Preparations? FDA conducted unannounced routine inspections of all Lorillard facilities At FDA’s request during the inspections, we provided: Over 5,000 pages of documents 127 SOPs (Standard Operating Procedures) Operations’ Work Instructions for ev

  88. Slide 88: FDA Inspector Feedback – Outstanding

    FDA Inspector Feedback – “Outstanding” Wrap-up session: Exceptional preparation (efficiency of responses and quality of information) “A Model of Cooperation” Inspectors praised our level of sophistication Provided FDA an opportunity to learn about the industry Established a baseline for GMP prepared

  89. Slide 89: What Impact Will CTP's New Director Have?

    What Impact Will CTP’s New Director Have On The Tobacco Industry? Outspoken tobacco control advocate Led FDA task force on tobacco regulations under Commissioner David Kessler Worked at American Legacy Foundation Consultant and lobbyist for pharma (NRTs) in private practice (Pinney Associates) Suppo

  90. Slide 90: What Impact Will CTP's New Director Have?

    What Impact Will CTP’s New Director Have on the Tobacco Industry? Mitch Zeller, JD Expected to drive a more aggressive regulatory agenda Committed to “Follow-the-Science” Required to navigate within FDA’s regulatory framework Top three priorities: SE submissions Deeming Regulation Menthol Although N

  91. Slide 91: FDA Announces First Decisions On New Tobacco Products

    “FDA Announces First Decisions On New Tobacco Products”

  92. Slide 92: FDA SE Orders Allow Marketing Of Two New Lorillard Products

    “…Today’s SE orders allow the marketing of two new Lorillard Tobacco Company tobacco products: Newport Non-Menthol Gold Box 100s and Newport Non-Menthol Gold Box. The agency has found these two products to be substantially equivalent to predicate products, based on the company’s submissions and othe

  93. Slide 93: Current Status Of E-cigarettes And Deeming Regulations

    What Is The Current Status Of E-cigarettes And Deeming Regulations? FDA announced intention to regulate e-cigarettes in 2011 Primary concern: Over Regulation Prevent clear public health benefits Inhibit new technological advancements Stifle product innovation Fair regulations are needed Ensure produ

  94. Slide 94: Current Status Of E-Cigarettes And Deeming Regulations

    What Is The Current Status Of E-Cigarettes And Deeming Regulations? Mr. Zeller appears to support e-cigarette’s harm reduction potential Deeming regulations expected this year We anticipate initial draft regulations to be somewhat restrictive Lorillard is prepared to vigorously respond with a harm r

  95. Slide 95: Summary

    Summary Lorillard’s compliance infrastructure is well established We have successfully passed routine inspections We are well prepared for GMPs when implemented Excellent communications have been established with CTP We have received the first and only SE Orders for new tobacco products We look forw

  96. Slide 96: But… What About Potential Regulatory Action on Menthol?

    But… What About Potential Regulatory Action on Menthol?

  97. Slide 97: Review of Menthol Science

    Review of Menthol Science William R. True, Ph.D. Senior Vice President Research and Development

  98. Slide 98: What Do We Mean by Sound Science

    What Do We Mean by Sound Science Robust design to support study objective / hypothesis Conclusions drawn clearly explained and supported by data Reproducible Full Transparency Data availability Data selection and statistical treatment explained clearly Study limitations Weight of evidence across mul

  99. Slide 99: Menthol Cigarettes are not More Dangerous than Non-Menthol

    The Science is Clear: Menthol Cigarettes are not More Dangerous than Non-Menthol Cigarettes “This review of the scientific evidence, which includes epidemiology studies, as well as those of biomarkers of exposure and harm, smoking topography, and toxicology and chemistry, clearly demonstrates that s

  100. Slide 100: Menthol Smokers Do Not Have Higher Risk Of Lung Cancer

    Menthol Smokers Do Not Have Higher Risk Of Lung Cancer (and Perhaps Less) Compared To Non-Menthol Smokers Risk of Lung Cancer Menthol Smokers vs. Non-menthol Smokers Higher Risk 2.00 Equal Risk 1.00 Lower Risk 0.00 *Statistically Significant 1Lee 2010 – “A combined analysis of lung cancer studies sh

  101. Slide 101: Biomarkers of Exposure Show No Difference

    Biomarkers of Exposure Show No Difference Between Menthol and Non-Menthol Smokers PM Total Exposure Study – 3,600 Adult Smokers, 31 States Biomarkers of Exposure – No difference in biomarkers of exposure – No difference when evaluated by race Vast majority of studies measuring biomarkers of exposure

  102. Slide 102: Biomarkers of Potential Harm Show No Difference

    Biomarkers of Potential Harm Show No Difference Between Menthol and Non-Menthol Smokers PM Total Exposure Study Only large study to examine differences in biomarkers of potential harm between menthol and non-menthol smokers Reported no difference in biomarkers of potential harm Biomarker No Differen

  103. Slide 103: Behavioral Science Does Not Support A Difference

    The Behavioral Science also DOES NOT Support a Difference in Public Health Impact Between Menthol and Non-Menthol Cigarettes No Difference African American Incidence Levels Initiation Cessation Youth smoking, incl. African Americans Transition to established smoking Based on weight of evidence of sc

  104. Slide 104: African American Smoking Incidence is Lower Than White

    Despite a Preference for Menthol, African American Smoking Incidence is LOWER Than White Smoking Incidence Smoking Incidence 20.6% 19.4% 19.0% 16.7% National Average Non-menthol 71.3% Menthol 83.3% 28.7% White African American Smoking incidence: NHIS (2011) and NSDUH (2011) 103 Menthol smokers: NHIS

  105. Slide 105: African American Smokers Begin Later, Lower Youth Smoking Rate

    And, African American Smokers Begin Smoking Later and Have A Much Lower Youth Smoking Rate Age Start Smoking 20.0 19.5 African American Menthol 19.0 18.5 18.0 White Menthol 17.5 17.0 16.5 White Non-menthol 16.0 15.5 15.0 NHIS NHANES NSDUH Youth Smoking Rate (12-17) 0 White African American Youth smo

  106. Slide 106: Vast Majority of Menthol Smokers are White

    Despite What Some May Suggest, The Vast Majority of Menthol Smokers are White There are over 2x more White menthol smokers than African American menthol smokers Menthol Smokers (in millions) 0 White African American Smoking incidence: NHIS (2011) and NSDUH (2011) 105 Menthol smokers: NHIS (2011), NS

  107. Slide 107: Menthol Share Up, Youth Smoking Rates Decreased

    Across All Demographics, as Menthol Market Share Has Increased, Youth Smoking Rates Have Steadily Decreased 35% 30% 25% 20% Menthol Market Share 15% Youth Smoking Rate 10% 5% 0% 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Menthol market share (MSAI) Youth smoking rate (NSDUH 201

  108. Slide 108: No Correlation Between Menthol Share and Youth Smoking, State Level

    There is No Correlation Between Menthol Share and Youth Smoking in the U.S., at the State Level

  109. Slide 109: No Correlation Internationally Between Youth Smoking and Menthol Share

    There is Also No Correlation between International Youth Smoking Prevalence and Menthol Market Share “We conclude that there is no evidence to support the hypothesis that greater availability of menthol cigarettes (as represented by market share) is associated with higher youth smoking prevalence –

  110. Slide 110: Smokers Choose Menthol for Flavor

    And Despite Claims That Menthol Makes Cigarettes Less Harsh, Smokers Disagree and Instead Choose Menthol for Flavor 2010 CPS-TUS reasons for smoking menthol/non-menthol cigarettes First national survey to contain these questions 100% 90% 80% Menthol 70% 60% Nonmenthol 50% 40% 30% 20% 10% 0% First wa

  111. Slide 111: Weight of Evidence Suggests No Difference in Cessation

    The Weight of Evidence of Studies Also Suggests No Difference in Cessation Cessation n = 37 Pre-TPSAC n= 31 Post-TPSAC n = 6 Adequate Methodology n = 17 No Difference or Effect Favorable Menthol n = 22 Pre-TPSAC n = 21 Post- TPSAC n = 1 Adequate Methodology n = 11 Mixed Results n = 10 Pre-TPSAC n =

  112. Slide 112: No Initiation Studies Used Adequate Methodology

    And, No “Initiation” Studies Used Adequate Methodology Initiation n = 13 Pre-TPSAC n = 10 Post-TPSAC n = 3 Adequate Methodology n = 0 No Difference Menthol or Effect Favorable n = 6 Pre- TPSAC n = 6 Post-TPSAC n = 0 Adequate Methodology n = 0 Mixed Results n = 3 Pre-TPSAC n = 2 Post-TPSAC n = 1 Adeq

  113. Slide 113: FDA Authors and TPSAC Agreed Additional Research Needed

    FDA Authors and even TPSAC Agreed that Additional Research on the Topic of Initiation is Needed Overall, there is a paucity of data on this topic. A lack of data prevents further conclusions on the role of menthol cigarettes in the initiation of smoking. - “Menthol and Initiation of Smoking” FDA dra

  114. Slide 114: Evidence Since TPSAC Report Does Not Support Disproportionate Regulation

    The Weight of Evidence from Menthol Research Since the TPSAC Report Does Not Support Disproportionate Regulation TPSAC New articles report that was discuss released menthol have been published since the chemistry) Scientific studies n=24 (epidemiology, biomarkers, topography, toxicology, – perceptio

  115. Slide 115: How did TPSAC reach its Conclusion?

    With the Evidence So Clear that There is No Difference, How did TPSAC reach its Conclusion? “Removal of menthol cigarettes from the marketplace would benefit public health in the United States.” TPSAC, March 2011

  116. Slide 116: TPSAC's Conclusions Driven by Model With Faulty Inputs

    TPSAC’s Menthol Conclusions Were Driven by a Model That Relied on Faulty Inputs Mendez model “To gain an understanding of the quantitative impact of menthol cigarette on public health, TPSAC turned to the results of models of smoking in the United States .” TPSAC provided inputs “.TPSAC provided spe

  117. Slide 117: Behavioral Studies Suffer from Methodological Flaws

    Behavioral Studies Relied on by TPSAC for Model Input Suffer from Methodological Flaws Covance evaluated methodology of studies Typical flaws in methodology Failure to use valid measures of study endpoint or failure to explain rationale for measures used Lack of appropriate statistical rigor Lack of

  118. Slide 118: TPSAC Relies on Nonnemaker 2010 for Key Input

    TPSAC Relies on Nonnemaker 2010 for Key Input to Mendez Model Uses data from American Legacy Longitudinal Tobacco Use Reduction Study (ALLTURS) ALLTURS data and questionnaire are not publicly available Nonnemaker has not responded to requests from Lorillard to provide the underlying data used in his

  119. Slide 119: Nonnemaker Falsely Imply Large Data Set Was Used

    Nonnemaker 2010 and 2012 Falsely Imply that a Large Data Set Was Used from Thousands of Subjects “We conducted secondary analysis of [ALLTURS], a longitudinal school-based study of 47,237 middle school and high school youth.” (Nonnemaker 2010) “The study was conducted in 83 schools in seven communit

  120. Slide 120: Nonnemaker 2010 and 2012 Report Dramatically Different Results

    Nonnemaker 2010 and 2012 Report Dramatically Different Results from Same Data Set 2010 – menthol experimenters progressed to established smoking at a rate 68% greater than non-menthol experimenters OR 1.68 (1.00-2.82) not statistically significant 2012 – rate was 80% greater – OR 1.80 (1.02-3.16) st

  121. Slide 121: Unexplained Anomalies Between Nonnemaker 2010 and 2012

    Unexplained Anomalies Exist Between Nonnemaker 2010 and 2012 Nonnemaker 2012 includes subjects that were excluded in 2010 analysis Nonnemaker 2012 inappropriately eliminates one group from denominator of calculations Some smokers are not accounted for in any group These differences likely explain wh

  122. Slide 122: Mendez Model Prediction of Excess Deaths Not Credible

    Mendez Model Prediction of Excess Deaths Due to Availability of Menthol is Simply NOT Credible Uses Nonnemaker 2010 progression rate of 68% greater for menthol smokers as a key input variable Mendez uses two key rates Proportion of non-menthol experimenters who become established smokers (56%) Propo

  123. Slide 123: Mendez Model Based on Nonnemaker 2010

    Mendez Model Based on Nonnemaker 2010 Cohort of potential Experimenters (W) 100% Proportion of Experimenters in Cohort (E) 30% Experimenters W*E 30.0% Proportion of Menthol among Experimenters (K4) 45% Menthol Experimenter W*E*K4 13.5% Proportion of Menthol Experimenters that become established smok

  124. Slide 124: Unrealistic Inputs Drive the TPSAC Conclusion

    Unrealistic Inputs Drive the TPSAC Conclusion Difference in progression of menthol experimenters (93%) and non-menthol experimenters (56%) to established smoking accounts for 91% of excess deaths reported by Mendez 297,219 of the 327,565 excess deaths by 2050 Basis of TPSAC’s conclusion: “Menthol ci

  125. Slide 125: Mendez Model Leads to Impossible Results

    Mendez Model Leads to Impossible Results Confidence interval is the range that is b ed to include the true parameter of the time – i.e. the margin of error Using the upper confidence interval of Nonnemaker 2012 rate of progression leads to impossible results OR = 1.80 (1.02-3.16) Using 3.16 in the m

  126. Slide 126: TPSAC's Conclusion was NOT Based on Sound Science

    TPSAC’s Conclusion was NOT Based on Sound Science A product of a biased and conflicted panel Relied on a single model that was not well understood Over reliance on a single flawed study for inputs to their model

  127. Slide 127: FDA Will Consider Countervailing Effects of Menthol Regulation

    And that the FDA will Consider the Countervailing Effects of Disproportionate Menthol Regulation as They are Required by Law 72% of current Menthol Sales Would Be Sold On Black Market Estimate from Compass Lexecon Report Black Market will be significant Increased youth access Counterfeit cigarettes

  128. Slide 128: Government Bodies Have Warned about Contraband Risks

    We Don’t Believe the FDA will Ignore Many Major Government Bodies that Have Warned about Contraband Risks Further, the illicit [tobacco] trade has been linked to organized crime and violent crime, and poses a serious risk to our national security.” — Department of Treasury Report to Congress, 2/4/20

  129. Slide 129: Going Forward

    Going Forward Waiting on FDA announcement on menthol FDA-NIH funded PATH Studies may provide additional information on menthol over the next several years – which should show no difference We continue to believe that the science does not provide a basis for regulating menthol cigarettes differently

  130. Slide 130: Regulation And Litigation Can Be Concerns

    While Lorillard’s Fundamentals Clearly Lead The Industry, Regulation And Litigation Can Be Concerns Agenda Introduction Bob Bannon – Investor Relations Strategic Plan Update Murray Kessler – Chairman, President & CEO Regulatory Update Neil Wilcox – SVP, Chief Compliance Officer Bill True – SVP, R&D

  131. Slide 131: Legal Update

    Legal Update Ron Milstein EVP, Legal & External Affairs, General Counsel & Secretary June 27, 2013

  132. Slide 132: Lorillard Litigation

    Lorillard Litigation History of successfully managing tobacco litigation – Successfully transitioned to new national counsel (HHR) in 2012 Challenges manageable going forward

  133. Slide 133: Lorillard Litigation (cont.)

    Lorillard Litigation (cont.) Product liability litigation Individual Class actions Health-care reimbursement Kent filter Other litigation FDA related

  134. Slide 134: Individual Cases

    Individual Cases Traditional individual cases West Virginia consolidated case Engle Progeny suits

  135. Slide 135: Traditional Individual Cases

    Traditional Individual Cases 200 150 100 50 0 Individual S&H Cases 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 27 cases pending against Lorillard

  136. Slide 136: Traditional Individual Lawsuits

    Traditional Individual Lawsuits Evans v. Lorillard (Superior Court, Boston, MA) December 2010 jury verdict against Lorillard $35M compensatory / $81M punitive damages assessed by jury decision Massachusetts on June Supreme 11, 2013 Judicial Court issued appellate Reversed new trial trial court on $8

  137. Slide 137: Traditional Individual Lawsuits

    Traditional Individual Lawsuits Two traditional individual trials scheduled for 2013 New York California

  138. Slide 138: West Virginia

    West Virginia then Multi-phase individual trial, trials with if common necessary issues proceeding first, 600 individual cases consolidated for liability phase Only 31 cases involved claims against Lorillard Defense one) verdict entered May 2013 on all counts (but – Only remaining count involves cer

  139. Slide 139: Engle Cases

    Engle Cases We have made progress reducing the number of Engle cases 7,600 4,520

  140. Slide 140: Engle Cases (cont.)

    Engle Cases (cont.) TRIAL RESULT INDUSTRY LORILLARD Trial to Verdict 96 13 Defense Verdicts 33 3 Plaintiff Verdicts 63 10 Trials Concluded before Verdict 28 5 Range of Loss on Plaintiff $1,400-$70.9M $4,500-$33M Verdicts

  141. Slide 141: Engle Cases (cont.)

    Engle Cases (cont.) • Four Engle trials scheduled in Q3 2013 • Appeals pending in FL and US Supreme Courts over Engle Phase 1 findings • Duke/Walker (11th Circuit) – Oral argument set for July 12, 2013 • Douglas (US Supreme Court) – Certiorari petition pending • To date, $15,500 paid by Lorillard in

  142. Slide 142: Class Actions

    Class Actions • No active suits pending against Lorillard • Lorillard is not a defendant in “Lights” class action cases

  143. Slide 143: Health Care Reimbursement Cases

    Health Care Reimbursement Cases • DOJ RICO suit – Last details implementing Judge Kessler’s order on corrective advertising to be addressed – Company expects to spend approximately $20M to comply and reserved in 1Q 2013 accordingly

  144. Slide 144: Kent Filter

    Kent Filter • Allege cigarette injury filter from asbestos in original Kent – Manufactured between 1952 and 1956 – Claims usually involve mesothelioma – Smoking and health not an issue • plants Worker claims from asbestos exposure in the • Smoker claims – 60 pending suits

  145. Slide 145: Kent Filter (cont.)

    Kent Filter (cont.) • Verdicts in 22 cases tried since 1991 (17 defense verdicts; 5 plaintiff verdicts) – Damages ranged from $140,000 to $2.25 million • Settlement strategy established to minimize economic loss • Several trials scheduled for 2013

  146. Slide 146: FDA

    FDA • TPSAC conflicts of interest suit pending – DC District Court • Graphic Warnings suit – Case over; industry victory – No appeal by FDA

  147. Slide 147: Summary

    Summary • Engle is company’s greatest litigation expense and risk • The Company is performing well defending Engle cases and the risk appears manageable • All other cases are declining, except Kent Filter • All cases appear manageable

  148. Slide 148: Regulation And Litigation Can Be Concerns

    While Lorillard’s Fundamentals Clearly Lead The Industry, Regulation And Litigation Can Be Concerns Agenda Introduction Strategic Plan Update Regulatory Update Legal Update Financial Guidance (Lorillard-Style) Additional Q&A Bob Bannon – Investor Relations Murray Kessler – Chairman, President & CEO

  149. Slide 149: Financial Guidance (Lorillard-Style)

    Financial Guidance (Lorillard-Style) David Taylor EVP, Finance and Planning & Chief Financial Officer June 27, 2013

  150. Slide 150: Financial Guidance (Lorillard-Style)

    Financial Guidance (Lorillard-Style) • Philosophy – no explicit earnings guidance • Promotes longer-term thinking and decision-making • Recognize the issues this may create

  151. Slide 151: Financial Guidance: Domestic Industry Shipments

    Financial Guidance (Lorillard-Style) Total Domestic Industry Shipments -3.1% Units in billions 401 -3.2% -4.1% 357 CAGR -1.7% 345 350 -3.2% -1.5% -5.0% -3.3% 300 -8.6% 293 286 -3.8% -3.5% 250 -2.3% -4.9% 200 Q1 2013* 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Source: MSA, Inc. domestic s

  152. Slide 152: Lorillard Outperforms Rest of Industry

    Financial Guidance (Lorillard-Style) Lorillard clearly outperforms rest of industry Total Domestic Industry Shipments +1.2% 100 CAGR to 100 Indexed Volume 80 CAGR -4.7% 2005 2006 2007 2008 2009 2010 2011 2012 Lorillard Rest of Industry Source: MSA, Inc. domestic shipment data

  153. Slide 153: Financial Guidance: Dividend Policy

    Financial Guidance (Lorillard-Style) Dividend Policy – 70%—75% of Earnings $2.50 Annualized Dividend Rate $2.20 $2.07 $1.73 $1.50 $1.50 $1.33 $1.23 $0.50 Q3 2008 Q3 2009 Q3 2010 Q1 2011 Q1 2012 Q1 2013 Source: Lorillard filings.

  154. Slide 154: Financial Guidance: Capital Needs

    Financial Guidance (Lorillard-Style) Capital Needs • Capital Expenditures ~ $70—$80 million per year • Other – blu eCigs acquisition $135 million in 2012 • Working capital investments to fund growth $100 Capital Expenditures $75 $74 $56 $51 $50 $44 $40 $25 $0 2008 2009 2010 2011 2012 Source: Lorilla

  155. Slide 155: Share Repurchases Continue To Be Attractive

    Financial Guidance (Lorillard-Style) Share repurchases continue to be attractive uses of cash $ 3.0 Cash Returned to Shareholders $7.3 Billion Total $ 2.5 Returned Share Repurchases $ 2.0 Dividends $ 1.5 $1,586 $ 1.0 $910 $ 716 $578 $ 0.5 $ 400 $631 $ 645 $723 $807 $ 0.0 $ 313 2008 2009 2010 2011 20

  156. Slide 156: Financial Guidance: Leverage

    Financial Guidance (Lorillard-Style) Leverage • Target is 1.5x – 2.0x debt to EBITDA • Not likely to change without change in current environment • Protect investment grade ratings • Currently at 1.8x $4,000 Gross Debt $3,500 $3,000 $3,000 $2,500 $2,000 $1,750 $1,000 $750 $0 2009 2010 2011 2012 2013

  157. Slide 157: Long-Term EPS Growth Rate Scenarios

    Financial Guidance (Lorillard-Style) Potential Long-Term EPS Growth Rate Scenarios – All Delivering Double-Digit Shareholder Return* Mid-Single Digit High-Single Digit Low-Double Digit • Heightened promotion • Normal historical pricing • Normal historical pricing environment • No new products • New

  158. Slide 158: Some Positive Factors in Place

    Financial Guidance (Lorillard-Style) Some positive factors in place: • Share repurchase program increased following $500 million debt issuance in May 2013 • Recent FDA authorization for Newport Non-Menthol Gold • Partial settlement of NPM dispute provides liquidity and some continuing earnings benef

  159. Slide 159: Incentive Compensation Structure Aligns With Goals

    Financial Guidance (Lorillard-Style) Incentive compensation structure aligns with goals Annual plan balance between Newport market share and operating profit Long-term incentives are paid in common shares with 3-year vesting – variable with EPS targets Source: Lorillard filings.

  160. Slide 160: Summary

    Summary All elements are in place to continue our history of superior financial results Poised to accelerate earnings growth: New products e-cigarette growth We remain committed to rewarding shareholders with cash returns

  161. Slide 161: Murray S. Kessler

    Murray S. Kessler Chairman, President and Chief Executive Officer

  162. Slide 162: Conclusions

    Conclusions Lorillard’s ongoing Strategic Plan has resulted in continued outperformance Incremental new products and blu eCigs should accelerate growth even further The right management team is in place to handle all potential regulatory and legal outcomes Lorillard remains committed to rewarding sh

  163. Slide 163: Questions

    Questions

  164. Slide 164: Appendix A: Regulation G Reconciliations

    Appendix A Regulation G Reconciliations Reconciliation of Reported (GAAP) to Adjusted (Non-GAAP) Results (Amounts in millions, except per share data) (Unaudited) Year ended December 31, 2011 Operating E-Cigarette Segment Income Diluted EPS Operating Income Reported (GAAP) results $1,892 $2.66 N/A GA

  165. Slide 165: Appendix A (cont.)

    Appendix A (cont.) Regulation G Reconciliations Reconciliation of Reported (GAAP) to Adjusted (Non-GAAP) Results (Amounts in millions, except per share data) (Unaudited) Quarter Ended March 31, 2013 Operating E-Cigarette Segment Income Diluted EPS Operating Income Reported (GAAP) results $561 $0.86

  166. Slide 166: Appendix A (cont.): Leverage Ratios

    Appendix A (cont.) Regulation G Reconciliations Leverage Ratios Proforma 2010 2011 2012 2013—Q1 2013—Q1 Adjusted operating income $ 1,725 $ 1,867 $ 1,883 $ 1,883 (1) $ 1,883 (1) Depreciation and amortization 35 37 39 39 39 Earnings before interest, taxes, depreciation and amortization (B) $ 1,760 $

  167. Slide 167: Appendix A (cont.)

    Appendix A (cont.) Regulation G Reconciliations Reconciliation of Reported (GAAP) to Adjusted (Non-GAAP) Results (Amounts in millions, except per share data) (Unaudited) Year ended December 31, 2011 Operating Gross Profit Income Net Income Diluted EPS Reported (GAAP) results $2,343 $1,892 $1,116 $2.

  168. Slide 168: Lorillard

    Lorillard

Lorillard — Investor Day (June 2013) on 6ix